Hear from a panel of experts discussing biomarker testing in non-small cell lung cancer
Hear from a panel of experts discussing implementing continuous glucose monitoring interventions to improve outcomes for members with diabetes.
The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.
Chronic lymphocytic leukemia (CLL) is a chronic
lymphoproliferative disorder (lymphoid neoplasm).
It is characterized by a progressive accumulation of
functionally incompetent B lymphocytes, which are
usually monoclonal in origin.
Hear from a panel of experts discussing exploring opportunities to improve quality of life for those with Amyotrophic Lateral Sclerosis (ALS).
The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.
Hear from a panel of experts discussing how to navigate the landscape of food allergies.
Hear from a panel of experts discussing how to optimize the management of inherited blood disorders.
This non-promotional, sponsored webinar will review health plan best practice recommendations for Chronic Lymphocytic Leukemia (CLL) with an impressive panel of oncology and managed care experts.
Recommendations for treatment initiation in CLL are stratified by disease stage using either the Rai staging system, which defines disease as low-, intermediate-, or high-risk; or the Binet staging system, which defines disease as stage A, B, or C based on the number of lymphoid areas involved and the presence of anemia or thrombocytopenia. Generally, treatment should be initiated in patients with active or progressive disease who are intermediate- or high-risk, or stage B or C.
Parenting a child with food allergies presents unique challenges. From grocery shopping to school accommodations to planning for daily activities, food allergies affect all aspects of a family’s life. Take a peek inside the life of a food allergy mom with the next installment of FARE’s Food For Thought videos.
